<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04754503</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A03063-36</org_study_id>
    <nct_id>NCT04754503</nct_id>
  </id_info>
  <brief_title>Survival and Quality of Life After Liver Transplantation in Patients Aged 65 and Over</brief_title>
  <acronym>LT 65+</acronym>
  <official_title>Survival and Quality of Life After Liver Transplantation in Patients Aged 65 and Over</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gérond'if</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gérond'if</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this non-interventional, single-center study is to assess survival and&#xD;
      associated factors at 1 year in patients aged 65 and over who received liver transplantation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The expected benefits of this study are to identify the preoperative risk factors of&#xD;
      mortality from liver transplant failure in patients aged 65 and over (90-day mortality and 1&#xD;
      and 3-year survival) will allow better selection. candidates for this age group. In the&#xD;
      current context of organ shortage, this study should make it possible to reduce the number of&#xD;
      risky transplants and thus improve the allocation of grafts.Inclusion of patients who meet&#xD;
      the inclusion criteria will be carried out during their hospitalization in the surgical&#xD;
      department of the hepato-bilary center.&#xD;
&#xD;
      Included patients will receive a standardized geriatric assessment in addition to the usual&#xD;
      assessment for a liver transplant.&#xD;
&#xD;
      The geriatric assessment will be carried out and conducted as follows: geriatric scores and&#xD;
      quality of life questionnaires. Two geriatricians will perform the physical examination and&#xD;
      blindly estimate each other's probability of survival at 90 days using a Likert scale.&#xD;
&#xD;
      Geriatricians will be blinded to hepatic data (reasons for transplantation). The consultation&#xD;
      as well as the completion of the questionnaire will be carried out during the&#xD;
      pre-transplantation assessment.&#xD;
&#xD;
      Survival and quality of life will be assessed at 3 and 12 months post-transplantaion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 9, 2021</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of survival and quality of life after liver transplantation according to the quality of life score</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detecting depression in the elderly according the Geriatric Depression Scale (GDS)</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of commorbidity risk according Charlson score</measure>
    <time_frame>At inclusion</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of the degree of patient dependence according &quot;Index of Independence in Activities of Daily Living&quot; KATZ scale</measure>
    <time_frame>12 Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of patient's level of dependence through an appreciation of instrumental activities of daily living according Lawton scale</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of quality of life according the SF-36 Health Status Questionnaire</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of the emotional, physical and financial burden on a caregiver according Zarit burden scale</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Patients Suitable for a Liver Transplant</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients over 65 years of age who are candidates for a liver transplant at the&#xD;
        participating center during the study period.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Candidates for liver transplantation&#xD;
&#xD;
          -  Having expressed non-oppostion to his participation in study and documented in his&#xD;
             medical file&#xD;
&#xD;
          -  With social coverage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency transplant patients&#xD;
&#xD;
          -  Patient already included in another study&#xD;
&#xD;
          -  Patient under guardianship or curatorship&#xD;
&#xD;
          -  Expressing his opposition to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duron Emmanuelle, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Geriatric Department, Paul Brousse Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle Dufour</last_name>
    <phone>+33 (0)185781010</phone>
    <email>isabelle.dufour@gerondif.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margot Bobin</last_name>
    <phone>+33 (0)185781010</phone>
    <email>margot.bobin@gerondif.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Geriatric Department, Paul Brousse Hospital</name>
      <address>
        <city>Villejuif</city>
        <state>Île-de-France</state>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle DURON, MD PhD</last_name>
      <phone>+33(0)145593843</phone>
      <email>emmanuelle.duron@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>August 7, 2021</last_update_submitted>
  <last_update_submitted_qc>August 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver transplant</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

